RxDoctor Payments Data

Ashley Tipper

Medical · Statesville, NCNPI 1629563945

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 1,369 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 55 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$23,134in general payments, 2019–2025

Across 1,369 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • AbbVie$3K
  • Johnson & Johnson$2K
  • Novartis$2K
  • UCB, Inc.$1K
  • Pfizer$1K
  • plus $10K from 49 others

What the payments were for

  • Food & beverage$22,52597%
  • Education$5963%
  • Entertainment$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,134 in reported general payments places this provider in the 95th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel MiniEtanercept45$337,302
Humira(Cf) PenAdalimumab34$336,584
Humira PenAdalimumab31$218,011
Actemra ActpenTocilizumab41$171,275
Cosentyx Unoready PenSecukinumab14$114,850
RinvoqUpadacitinib18$111,008
Taltz AutoinjectorIxekizumab15$101,990
Cosentyx Sensoready PenSecukinumab13$101,974
EnbrelEtanercept13$97,002
Xeljanz XrTofacitinib Citrate13$95,685
OtezlaApremilast18$87,296
TymlosAbaloparatide24$64,332
OrenciaAbatacept11$62,969
KevzaraSarilumab11$46,298
Evenity (2 Syringes)Romosozumab-Aqqg12$29,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla, Evenity (2 Syringes)$3,936$213,48143 claims
AbbVieRinvoq$3,015$111,00818 claims
Radius Health, Inc.Tymlos$770$64,33224 claims
E.r. Squibb & Sons, L.L.C.Orencia$482$62,96911 claims
SanofiKevzara$458$46,29811 claims
Hikma Pharmaceuticals USAMitigare$16$2,92016 claims
Scilex Pharmaceuticals Inc.Colchicine$130$59829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 medical providers in North Carolina.

Other medical in Statesville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →